Table 3.
Factors associated with early brain metastases (≤36 months)
| Variables | Univariate analysis | Multivariate analysis* | ||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | p | HR | 95 % CI | p | |
| Discovery Cohort A | ||||||
| ER negative versus positive | 3.3 | 1.1–10.0 | 0.03 | 2.8 | 0.9–9.1 | 0.07 |
| Visceral site of first distant relapse | 4.5 | 1.9–10.7 | 0.001 | 7.4 | 2.4–22.3 | <0.001 |
| 13-Gene expression high versus low | 5.6 | 1.9–16.5 | 0.002 | 8.5 | 2.6–28.0 | <0.001 |
| 3-Gene classifier high versus low | 3.7 | 1.3–11.1 | 0.01 | 5.3 | 1.6–16.7 | 0.005 |
| Trastuzumab therapy for metastatic disease no versus yes | 3.3 | 1.1–10.0 | 0.02 | 5.0 | 1.4–10.0 | 0.009 |
| Validation Cohort B | ||||||
| ER negative versus positive | 2.5 | 0.9–10.0 | 0.09 | 5.0 | 1.1–10.0 | 0.04 |
| Visceral site of first distant relapse | 5.9 | 1.8–19.7 | 0.003 | 6.1 | 1.5–25.6 | 0.01 |
| 3-Gene classifier high versus low | 1.2 | 0.3–20.0 | 0.8 | NC | ||
| Grade high versus low | 3.3 | 1.1–14.3 | 0.03 | 3.8 | 0.9–16.7 | 0.07 |
| Trastuzumab therapy for metastatic disease no versus yes | 2.5 | 1.0–10.0 | 0.06 | 10.0 | 2.0–100.0 | 0.008 |